Related Experiment Video
Updated: Apr 17, 2026
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
[Targeted therapies in non-small cell lung cancer in 2014]
1Service de pneumologie, nouvel hôpital civil, 1, place de L'Hôpital, 67091 Strasbourg, France.
Abstract:
For several years, the identification of molecular sequencing alterations has considerably changed the perception and treatment of non-small cell lung cancer (NSCLC). These alterations have been defined as "driver mutations", such as mutations in EGFR and EML4-ALK fusion gene, and are highly sensitive to specific therapies. Other targets have also been identified recently. Personalized medicine is now a reality for patients with advanced NSCLC on the basis of routine screening for EGFR, HER2, KRAS, BRAF, PI3KCA mutations and EML4-ALK rearrangement. This article describes identified biomarkers, available targeted therapies, and the main clinical research approaches in NSCLC.
Insights
Molecular sequencing in non-small cell lung cancer (NSCLC) identifies driver mutations like EGFR and EML4-ALK. These genetic alterations guide personalized therapies, making targeted treatments a reality for advanced NSCLC patients.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Molecular sequencing has revolutionized the understanding and treatment of non-small cell lung cancer (NSCLC).
- Driver mutations, such as EGFR and EML4-ALK fusions, are key targets for specific therapies.
- Personalized medicine is increasingly important for advanced NSCLC management.
Purpose of the Study:
- To review identified molecular biomarkers in NSCLC.
- To discuss currently available targeted therapies.
- To outline main clinical research approaches for NSCLC.
Main Methods:
- Review of scientific literature on NSCLC molecular alterations.
- Analysis of identified driver mutations and their therapeutic implications.
- Description of routine screening protocols for NSCLC biomarkers.
Main Results:
- Identification of key molecular targets including EGFR, HER2, KRAS, BRAF, PI3KCA mutations, and EML4-ALK rearrangement.
- Confirmation that these alterations are sensitive to specific targeted therapies.
- Establishment of personalized medicine approaches based on molecular screening.
Conclusions:
- Routine molecular screening is essential for personalized treatment of advanced NSCLC.
- Targeted therapies based on identified biomarkers offer improved outcomes.
- Ongoing clinical research continues to expand therapeutic options for NSCLC.
More Related Videos
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:24Modified-Release Drug Delivery Systems: Site-Targeted